Biohaven (BHVN) Other Non-Current Liabilities (2021 - 2026)
Biohaven (BHVN) posted Other Non-Current Liabilities of $4.6 million for Q1 2026, down 0.59% sequentially from $4.6 million in Q4 2025, and down 94.84% YoY from $88.3 million in Q1 2025.
Analysis
Biohaven (BHVN) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven has reported Other Non-Current Liabilities for 6 years, with the latest figure at $4.6 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 94.84% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 94.84% YoY) and the FY2025 annual result came in at $4.6 million, down 1.72% from the prior year.
- Other Non-Current Liabilities declined to $4.6 million in Q1 2026 per BHVN's latest filing, from $4.6 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $268.3 million in Q3 2025 and troughed at $2.2 million in Q4 2023.
- A 5-year average of $43.9 million and a median of $4.6 million in 2026 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities jumped 5849.32% in 2025, then tumbled 94.84% in 2026.
- Over 5 years, Other Non-Current Liabilities stood at $2.4 million in 2022, then dropped by 6.85% to $2.2 million in 2023, then soared by 107.71% to $4.7 million in 2024, then decreased by 1.72% to $4.6 million in 2025, then retreated by 0.59% to $4.6 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $4.6 million, $4.6 million, and $268.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.49 Mn |
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.64 Mn |
| Mar 31, 2025 | 4.61 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 12.32 Mn |
| Jun 30, 2024 | 12.18 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 2.52 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Dec 31, 2021 | 2.64 Mn |